Table 3.

Outcomes on additional analyses (6 weeks of treatment)

Placebo, meanBetamethasone, meanMean difference (95% CI)P-value
Assessed redness, mmVAS18.917.9−0.52 (−5.50 to 4.47)0.835
Assessed purpleness, mmVAS7.18.31.42 (−2.46 to 5.31)0.461
Assessed oedema, mmVAS5.57.52.24 (−2.16 to 6.65)0.307
Assessed ulceration, mmVAS0.60.2−0.42 (−1.42 to 0.57)0.392
  • VAS = visual analogue scale.